Chen L, et al. - Given that systemic inflammation response index (SIRI = N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to anticipate the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition, researchers conducted this retrospective study to assess the potential prognostic significance of SIRI in patients with breast cancer undergoing neoadjuvant chemotherapy. The sample consisted of 262 breast cancer patients treated with neoadjuvant chemotherapy. To analyze the prognostic value of SIRI, univariate and multivariate Cox proportional hazards regression models were used. Findings suggested that pretreatment SIRI with the benefit of repeatable, easy, and non-invasive is a useful prognostic measure for breast cancer patients who have undergone neoadjuvant chemotherapy and is a positive biomarker for breast cancer in decision making on treatment strategy.